STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144/A] HOOKIPA Pharma Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144/A
Rhea-AI Filing Summary

HOOKIPA Pharma Inc. filed a Form 144/A reporting a proposed sale of 25,172 shares of common stock to be executed on 08/19/2025 through Maxim Group on the NASDAQ. The filing lists an aggregate market value of $20,155 for the shares and shows 9,789,622 shares outstanding.

The securities were acquired as restricted stock units on 07/22/2024 (amount: 54,347) and the notice states the intended payment is compensation. The filing also discloses a recent sale on 07/23/2025 of 29,176 shares for $26,911. The signer represents no undisclosed material adverse information about the issuer.

Positive
  • Transparent filing of planned insider sale with broker, date, and amount disclosed
  • Includes recent sale activity (29,176 shares on 07/23/2025 for $26,911), improving market transparency
  • Acquisition method disclosed (Restricted Stock Units dated 07/22/2024) and payment nature (compensation)
Negative
  • None.

Insights

TL;DR: Routine insider sale disclosure; size is small relative to shares outstanding and unlikely to be material to valuation.

The Form 144/A documents a planned sale of 25,172 common shares by a person who acquired 54,347 RSUs in July 2024. With 9.79 million shares outstanding, the proposed sale represents a small fraction of equity (<0.26%). The filing provides transaction timing, broker identity, and recent past sales, which supports market transparency. There is no earnings or operational data here to reassess company fundamentals.

TL;DR: Disclosure complies with Rule 144 reporting elements; includes the required representations and broker details.

The submission identifies the broker (Maxim Group), sale date, acquisition method (RSUs), and past three-month sale activity, satisfying key Form 144 requirements. The signer affirms absence of undisclosed material adverse information, and the filing flags the transaction as compensation-related. From a compliance perspective, the document appears complete for a Rule 144 notice; it does not raise immediate regulatory red flags based on the provided fields.

144/A: Filer Information

144/A: Issuer Information

144/A: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

144/A: Remarks and Signature

FAQ

What shares does HOOKIPA (HOOK) plan to sell under this Form 144/A?

The filer plans to sell 25,172 shares of HOOKIPA common stock on 08/19/2025 via Maxim Group on the NASDAQ.

How many HOOKIPA shares are outstanding according to the filing?

The filing reports 9,789,622 shares outstanding.

When were the securities being sold originally acquired?

The securities were acquired as Restricted Stock Units on 07/22/2024, totaling 54,347 units.

Did the filer sell any HOOKIPA shares in the past three months?

Yes. The filer sold 29,176 shares on 07/23/2025 for gross proceeds of $26,911.

What is the aggregate market value of the proposed sale?

The aggregate market value reported for the 25,172 shares is $20,155.

Does the filing state whether undisclosed material information exists?

The signer represents by signature that they do not know of any material adverse information about the issuer that has not been publicly disclosed.
Hookipa Pharma

OTC:HOOK

HOOK Rankings

HOOK Latest News

HOOK Latest SEC Filings

HOOK Stock Data

11.01M
8.04M
19.27%
32.94%
0.29%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK